Upadacitinib sustains its efficacy in non-radiographic axial spondyloarthritis through 2 years without presenting any new ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

Building a retirement portfolio of $1 million or more is within reach for many Americans. AbbVie (NYSE: ABBV) is a great ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...

Explore some of the top defensive stocks to buy and hold ahead of Donald Trump's Liberation Day tariffs next week ...

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...